Switch theme
Sign up to access all valuation multiples
Semler Scientific Inc is a United States based company that is engaged in providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. It focuses on developing, manufacturing, and marketing proprietary products and services that assist customers, including insurance plans, physicians, and risk assessment groups, in evaluating and treating chronic diseases. The company markets its vascular-testing product under the QuantaFlo brand, which is a four-minute in-office blood flow test. also invest in bitcoin and have adopted bitcoin as its treasury reserve asset. Company's healthcare technology solutions business is predominant operational focus, providing cash flows and enabling it to pursue bitcoin.
2007
79
LTM Revenue $43.6M
Last FY EBITDA $21.5M
$659M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Semler Scientific has a last 12-month revenue (LTM) of $43.6M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Semler Scientific achieved revenue of $56.3M and an EBITDA of $21.5M.
Semler Scientific expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Semler Scientific valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $43.6M | XXX | $56.3M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $51.5M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 92% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $21.5M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 38% | XXX | XXX | XXX |
| EBIT | n/a | XXX | $20.9M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | 37% | XXX | XXX | XXX |
| Net Profit | -$0.8M | XXX | $40.9M | XXX | XXX | XXX |
| Net Margin | -2% | XXX | 73% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Semler Scientific's stock price is $42.
Semler Scientific has current market cap of $573M, and EV of $659M.
See Semler Scientific trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $659M | $573M | XXX | XXX | XXX | XXX | $0.52 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Semler Scientific has market cap of $573M and EV of $659M.
Semler Scientific's trades at 11.7x EV/Revenue multiple, and 30.6x EV/EBITDA.
Equity research analysts estimate Semler Scientific's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Semler Scientific has a P/E ratio of -704.8x.
See valuation multiples for Semler Scientific and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $573M | XXX | $573M | XXX | XXX | XXX |
| EV (current) | $659M | XXX | $659M | XXX | XXX | XXX |
| EV/Revenue | 15.1x | XXX | 11.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 30.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 31.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -704.8x | XXX | 14.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -4.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSemler Scientific's last 12 month revenue growth is -25%
Semler Scientific's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.4M for the same period.
Semler Scientific's rule of 40 is 9% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Semler Scientific's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Semler Scientific and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -25% | XXX | -24% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 38% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 9% | XXX | 13% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 23% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 54% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Semler Scientific acquired XXX companies to date.
Last acquisition by Semler Scientific was XXXXXXXX, XXXXX XXXXX XXXXXX . Semler Scientific acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Semler Scientific founded? | Semler Scientific was founded in 2007. |
| Where is Semler Scientific headquartered? | Semler Scientific is headquartered in United States of America. |
| How many employees does Semler Scientific have? | As of today, Semler Scientific has 79 employees. |
| Who is the CEO of Semler Scientific? | Semler Scientific's CEO is Dr. Douglas Murphy-Chutorian, M.D.. |
| Is Semler Scientific publicy listed? | Yes, Semler Scientific is a public company listed on NAS. |
| What is the stock symbol of Semler Scientific? | Semler Scientific trades under SMLR ticker. |
| When did Semler Scientific go public? | Semler Scientific went public in 2014. |
| Who are competitors of Semler Scientific? | Similar companies to Semler Scientific include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Semler Scientific? | Semler Scientific's current market cap is $573M |
| What is the current revenue of Semler Scientific? | Semler Scientific's last 12 months revenue is $43.6M. |
| What is the current revenue growth of Semler Scientific? | Semler Scientific revenue growth (NTM/LTM) is -25%. |
| What is the current EV/Revenue multiple of Semler Scientific? | Current revenue multiple of Semler Scientific is 15.1x. |
| Is Semler Scientific profitable? | Yes, Semler Scientific is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
